ProKidney Corp.
PROK
$0.09
Change (1 day)
$4.44
Year High
$1.18
Year Low
Categories
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
P/E ratio for ProKidney Corp. (PROK)
P/E ratio as of 2023: -3.10
According to ProKidney Corp.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -3.10. At the end of 2022 the company had a P/E ratio of -2.85.
P/E ratio history for ProKidney Corp. from 2019 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -3.10 |
| 2022 | -2.85 |
| 2021 | -33.48 |
| 2020 | -70.49 |
| 2019 | -9.97 |